IMI2 has launched a call for Diabetic Kidney Disease Biomarkers (DKD-BM) including:
- Generating candidate biomarkers from existing clinical longitudinal databases, including the possibility that the studies generating these databases might be expanded by these efforts;
- Using these clinical biomarkers to assess preclinical model systems, and select the most appropriate for future translational investigations;
- Back-translating clinical database findings to develop improved in vitro and in vivo models of DKD
Incorporating these novel biomarkers into clinical trials in order to enhance the precision of application and chances of success of future novel therapeutics aimed at slowing and/or reversing this disease.
More information and full text of the call can be found at the IMI website: http://www.imi.europa.eu/content/stage-1-16